US20140329786A1 - Combination treatment of cancer - Google Patents
Combination treatment of cancer Download PDFInfo
- Publication number
- US20140329786A1 US20140329786A1 US14/361,718 US201214361718A US2014329786A1 US 20140329786 A1 US20140329786 A1 US 20140329786A1 US 201214361718 A US201214361718 A US 201214361718A US 2014329786 A1 US2014329786 A1 US 2014329786A1
- Authority
- US
- United States
- Prior art keywords
- combination
- pharmaceutically acceptable
- cancer
- treatment
- azd5363
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
Definitions
- Cancer is also a major cause of morbidity in the UK with nearly 260,000 new cases (excluding non-melanoma skin cancer) registered in 1997. Cancer is a disease that affects mainly older people, with 65% of cases occurring in those over 65. Since the average life expectancy in the UK has almost doubled since the mid nineteenth century, the population at risk of cancer has grown. Death rates from other causes of death, such as heart disease, have fallen in recent years while deaths from cancer have remained relatively stable. The result is that 1 in 3 people will be diagnosed with cancer during their lifetime and 1 in 4 people will die from cancer. In people under the age of 75, deaths from cancer outnumber deaths from diseases of the circulatory system, including ischaemic heart disease and stroke. In 2000, there were 151,200 deaths from cancer. Over one fifth (22%) of these were from lung cancer, and a quarter (26%) from cancers of the large bowel, breast and prostate.
- this period is within 8 days.
- this period is within 4 days.
- this period is within 3 days.
- this period is within 24 hours.
- the other combination partner refers to MDV-3100; AZD3514; abiraterone, or an ester prodrug thereof; or bicalutamide; in order to provide a range of further embodiments of the invention.
- a combination comprising AZD5363 with MDV-3100.
- the cancer is in a non-metastatic state.
- a pharmaceutical composition which comprises AZD5363, or a pharmaceutically acceptable salt thereof; and abiraterone, or a pharmaceutically acceptable salt thereof; in association with a pharmaceutically acceptable diluent or carrier.
- the combination of the present invention might be used to treat a patient who has no metastases to stop them occurring, or to lengthen the time period before they occur, and to a patient who already has metastases to treat the metastases themselves.
- the treatment of cancer may refer to treatment of an established primary tumour or tumours and developing primary tumour or tumours.
- a pharmaceutical composition which comprises AZD5363, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier; in combination with a pharmaceutical composition which comprises ‘the other combination partner’ (as defined above), or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier, for use in the treatment of cancer.
- kits comprising AZD5363, or a pharmaceutically acceptable salt thereof; and ‘the other combination partner’ (as defined above) or a pharmaceutically acceptable salt thereof; optionally with instructions for use; for use in the treatment of cancer.
- the AZD5363 is dosed to a patient at 300-1100 mg per day on the days when it is dosed, and it is dosed for two consecutive days and then not dosed for five consecutive days thereafter within a seven day dosage cycle.
- the ‘other combination partner’ (as defined above) will normally be administered (i.e. dosed) to a warm-blooded animal at a unit dose, of an amount known to the skilled practitioner as a therapeutically effective dose.
- the active ingredients may be compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition.
- Dosage unit forms will generally contain about 20 mg to about 500 mg of each active ingredient.
- the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.
- the dosage of each of the drugs and their proportions have to be composed so that the best possible treatment effects, as defined by national and international guidelines (which are periodically reviewed and re-defined), will be met.
- the abiraterone acetate is dosed orally to a patient at 750-1250 mg per day on the days when it is dosed, and it is dosed every day of the week. (i.e. continuous dosing).
- the abiraterone acetate is dosed orally to a patient at 800-1200 mg per day on the days when it is dosed, and it is dosed every day of the week. (i.e. continuous dosing).
- the abiraterone acetate is dosed orally to a patient at 900-1100 mg per day on the days when it is dosed.
- the abiraterone acetate is dosed orally to a patient at 900-1100 mg per day on the days when it is dosed, and it is dosed every day of the week. (i.e. continuous dosing).
- the MDV-3100 is dosed orally to a patient at 150-170 mg per day on the days when it is dosed.
- FIG. 2 Inhibition of cell growth and enhanced cell death in VCAP cells from combination use of AZD5363 with MDV3100.
- ‘Tz’ represents the number of live cells at time zero
- ‘C’ represents the control growth
- ‘Ti’ represents the number of live cells in the presence of each drug regimen. This formula gives a growth percentage from ⁇ 100% to +100%. Negative scores are for cell killing and positive scores are for anti-proliferation. The data are presented in FIG. 1 and FIG. 2 . Synergism of the drug combination was evaluated using a unified approach described by C. Harbron (Stat. Med. 2010 Jul. 20; 29(16): 1746-56).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/361,718 US20140329786A1 (en) | 2011-11-30 | 2012-11-30 | Combination treatment of cancer |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161564975P | 2011-11-30 | 2011-11-30 | |
PCT/GB2012/052969 WO2013079964A1 (en) | 2011-11-30 | 2012-11-30 | Combination treatment of cancer |
US14/361,718 US20140329786A1 (en) | 2011-11-30 | 2012-11-30 | Combination treatment of cancer |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2012/052969 A-371-Of-International WO2013079964A1 (en) | 2011-11-30 | 2012-11-30 | Combination treatment of cancer |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/018,157 Continuation US9737540B2 (en) | 2011-11-30 | 2016-02-08 | Combination treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
US20140329786A1 true US20140329786A1 (en) | 2014-11-06 |
Family
ID=47295082
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/361,718 Abandoned US20140329786A1 (en) | 2011-11-30 | 2012-11-30 | Combination treatment of cancer |
US15/018,157 Active US9737540B2 (en) | 2011-11-30 | 2016-02-08 | Combination treatment of cancer |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/018,157 Active US9737540B2 (en) | 2011-11-30 | 2016-02-08 | Combination treatment of cancer |
Country Status (25)
Country | Link |
---|---|
US (2) | US20140329786A1 (es) |
EP (1) | EP2785349B2 (es) |
JP (1) | JP6309454B2 (es) |
KR (1) | KR102035361B1 (es) |
CN (1) | CN103945849B (es) |
AU (2) | AU2012321110B2 (es) |
CA (1) | CA2856646C (es) |
CY (1) | CY1122624T1 (es) |
DK (1) | DK2785349T4 (es) |
ES (1) | ES2762250T5 (es) |
FI (1) | FI2785349T4 (es) |
HK (1) | HK1202253A1 (es) |
HR (1) | HRP20191982T4 (es) |
HU (1) | HUE046667T2 (es) |
IL (1) | IL232530B (es) |
LT (1) | LT2785349T (es) |
MX (1) | MX367640B (es) |
MY (1) | MY175800A (es) |
PL (1) | PL2785349T5 (es) |
PT (1) | PT2785349T (es) |
RS (1) | RS59493B2 (es) |
RU (1) | RU2640485C2 (es) |
SG (1) | SG11201401471PA (es) |
SI (1) | SI2785349T2 (es) |
WO (1) | WO2013079964A1 (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018015958A1 (en) | 2016-07-21 | 2018-01-25 | Hadasit Medical Research Services And Development Ltd. | Ar antagonists or inhibitors for use in treating glioblastoma |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100048524A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
EP2350096B1 (en) | 2008-10-02 | 2019-12-11 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
AU2010210422A1 (en) | 2009-02-05 | 2011-08-18 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens |
SG10201907588XA (en) | 2010-02-16 | 2019-09-27 | Aragon Pharmaceuticals Inc | Androgen Receptor Modulators And Uses Thereof |
EP2663189B1 (en) | 2011-01-11 | 2018-07-04 | Novartis AG | Combination of bortezomib with afuresertib and use thereof in the treatment of cancer |
US20150005265A1 (en) * | 2011-12-22 | 2015-01-01 | Susan Stewart | Methods and compositions for combination therapy using p13k/mtor inhibitores |
AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
ES2836424T3 (es) | 2012-09-26 | 2021-06-25 | Aragon Pharmaceuticals Inc | Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración |
JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
EP4066841A1 (en) | 2013-03-14 | 2022-10-05 | University of Maryland, Baltimore | Androgen receptor down-regulating agents and uses thereof |
SG11201600525XA (en) | 2013-08-12 | 2016-02-26 | Tokai Pharmaceuticals Inc | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
CN109806266A (zh) * | 2013-10-01 | 2019-05-28 | 诺华股份有限公司 | 用于癌症治疗的组合及其应用 |
WO2015049650A1 (en) * | 2013-10-01 | 2015-04-09 | Glaxosmithkline Intellectual Property (No.2) Limited | Enzalutamide in combination with afuresertib for the treatment of cancer |
WO2015116696A1 (en) | 2014-01-28 | 2015-08-06 | Massachusetts Institute Of Technology | Combination therapies and methods of use thereof for treating cancer |
US10722527B2 (en) | 2015-04-10 | 2020-07-28 | Capsugel Belgium Nv | Abiraterone acetate lipid formulations |
TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
ES2884064T3 (es) * | 2016-12-16 | 2021-12-10 | Kangpu Biopharmaceuticals Ltd | Composición combinada que comprende un compuesto benzoheterocíclico y un modulador de la vía de los receptores androgénicos y usos de la misma |
CN107670048B (zh) | 2017-08-30 | 2019-04-26 | 南京明臻医药科技有限公司 | 具有协同抗癌活性的中间体药物和聚乙二醇偶联协同抗癌药物、及其制备方法和应用 |
JP2020534320A (ja) * | 2017-09-22 | 2020-11-26 | ディスパーソル テクノロジーズ リミテッド ライアビリティ カンパニー | アビラテロン環状オリゴマー薬学的製剤ならびにその形成法および投与法 |
KR20200070334A (ko) | 2017-10-16 | 2020-06-17 | 아라곤 파마슈티컬스, 인코포레이티드 | 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐 |
CN108486041A (zh) * | 2018-03-28 | 2018-09-04 | 华南农业大学 | PI3K/Akt信号通路在鸡胚成纤维细胞内对马立克氏病毒增殖的应用及其检测方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080161404A1 (en) * | 2005-02-23 | 2008-07-03 | Astrazeneca Ab | Bicalutamide for Delivering Increasing Steady State Plasma Levels |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE637271A (es) | 1963-04-04 | 1900-01-01 | ||
ATE28864T1 (de) | 1982-07-23 | 1987-08-15 | Ici Plc | Amide-derivate. |
CA2132449C (en) | 1992-03-31 | 2002-09-10 | Susan E. Barrie | 17 - substituted steroids useful in cancer treatment |
US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
GB9312853D0 (en) | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
JP2001519766A (ja) | 1996-04-03 | 2001-10-23 | メルク エンド カンパニー インコーポレーテッド | ファルネシルタンパク質トランスフェラーゼの阻害剤 |
US6432947B1 (en) | 1997-02-19 | 2002-08-13 | Berlex Laboratories, Inc. | N-heterocyclic derivatives as NOS inhibitors |
IL133672A0 (en) | 1997-06-27 | 2001-04-30 | Vivorx Pharmaceuticals Inc | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
WO1999007703A1 (en) | 1997-08-05 | 1999-02-18 | Pfizer Products Inc. | 4-AMINOPYRROLE(3,2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS |
US6162804A (en) | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
SK18542000A3 (sk) | 1998-06-04 | 2001-12-03 | Abbott Laboratories | Protizápalové zlúčeniny inhibujúce bunkovú adhéziu |
PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
US6262066B1 (en) | 1998-07-27 | 2001-07-17 | Schering Corporation | High affinity ligands for nociceptin receptor ORL-1 |
WO2000075145A1 (en) | 1999-06-03 | 2000-12-14 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
US7160890B2 (en) | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
HUP0301114A3 (en) | 2000-06-26 | 2004-11-29 | Pfizer Prod Inc | Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents and pharmaceutical compositions containing them |
AU9378801A (en) | 2000-08-31 | 2002-03-13 | Hoffmann La Roche | Quinazoline derivatives as alpha-1 adrenergic antagonists |
CN1263757C (zh) | 2000-12-01 | 2006-07-12 | Osi制药公司 | 特异于腺苷a1,a2a和a3受体的化合物及其应用 |
US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
US6673802B2 (en) | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
US20020182204A1 (en) | 2001-03-23 | 2002-12-05 | Marie-Christine Bissery | Combination of a taxane and a cyclin-dependent kinase |
EP1474425B9 (en) | 2002-01-07 | 2008-07-02 | Eisai Co., Ltd. | Deazapurines and uses thereof |
TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
MEP16308A (en) | 2002-05-17 | 2010-06-10 | Aventis Pharma Sa | Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer |
ES2464157T3 (es) | 2002-06-26 | 2014-05-30 | Ono Pharmaceutical Co., Ltd. | Remedios para enfermedades causadas por contracción o dilatación vascular |
US20040138238A1 (en) | 2002-08-08 | 2004-07-15 | Dhanoa Dale S. | Substituted aminopyrimidine compounds as neurokinin antagonists |
US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
AU2003265636A1 (en) | 2002-09-06 | 2004-03-29 | Smithkline Beecham Corporation | Pyrrolo(2, 3-d)pyrimidine-4-yl and purin-6-yl urea compounds |
CA2505529C (en) | 2002-11-08 | 2013-12-24 | President And Fellows Of Harvard College | Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors |
NZ540495A (en) | 2002-12-04 | 2007-09-28 | Eisai R&D Man Co Ltd | 1,3-Dihydro-imidazole fused-ring compound |
US7332525B2 (en) * | 2003-01-17 | 2008-02-19 | Castle Erik P | Method of treatment of prostate cancer and composition for treatment thereof |
EP1444982A1 (de) | 2003-02-06 | 2004-08-11 | Merckle Gmbh | Verwendung von Purinderivaten als selektive Kinase-Inhibitoren |
JP2006519846A (ja) | 2003-03-10 | 2006-08-31 | シェーリング コーポレイション | 複素環式キナーゼインヒビター:使用および合成の方法 |
US20060128956A1 (en) | 2003-04-21 | 2006-06-15 | Ustav Organicke Chemie A Biochemie Akademie Ved Ceske Republiky | (Purin-6-yl) amino acid and production method thereof |
FR2856685B1 (fr) | 2003-06-25 | 2005-09-23 | Merck Sante Sas | Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
EP1663204B1 (en) | 2003-08-29 | 2014-05-07 | Exelixis, Inc. | C-kit modulators and methods of use |
WO2005044181A2 (en) | 2003-09-09 | 2005-05-19 | Temple University-Of The Commonwealth System Of Higher Education | Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors |
TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
KR101223914B1 (ko) | 2003-11-21 | 2013-01-18 | 어레이 바이오파마 인크. | Akt 단백질 키나제 억제제 |
WO2005063704A1 (ja) | 2003-12-25 | 2005-07-14 | Ono Pharmaceutical Co., Ltd. | アゼチジン環化合物およびその医薬 |
CA2563699C (en) | 2004-04-23 | 2014-03-25 | Exelixis, Inc. | Kinase modulators and method of use |
UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
JP5274842B2 (ja) | 2004-12-28 | 2013-08-28 | エグゼリクシス, インコーポレイテッド | 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター(p70S6K、Akt−1およびAkt−2)としての[1H−ピペラゾ[3,4−d]ピリミジン−4−イル]−ピペラジンまたは[1H−ピペラゾ[3,4−d]ピリミジン−4−イル]−ピペラジン化合物 |
FR2880540B1 (fr) | 2005-01-13 | 2008-07-11 | Aventis Pharma Sa | Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90 |
FR2880626B1 (fr) | 2005-01-13 | 2008-04-18 | Aventis Pharma Sa | Derives de la purine, compositions les contenant et utilisation |
US7423043B2 (en) | 2005-02-18 | 2008-09-09 | Lexicon Pharmaceuticals, Inc. | 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds |
PT2444085E (pt) | 2005-05-13 | 2015-06-11 | Univ California | Compostos de diaril-hidantoínas como antagonistas do recetor androgénio para tratamento de cancro |
US20060281768A1 (en) | 2005-06-10 | 2006-12-14 | Gaul Michael D | Thienopyrimidine and thienopyridine kinase modulators |
JP5071374B2 (ja) | 2005-07-14 | 2012-11-14 | アステラス製薬株式会社 | ヘテロ環ヤヌスキナーゼ3阻害剤 |
US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
KR101643416B1 (ko) | 2005-08-31 | 2016-07-27 | 아브락시스 바이오사이언스, 엘엘씨 | 증가된 안정성을 가진 수 난용성 약물의 조성물 및 제조방법 |
CA2620585C (en) | 2005-08-31 | 2015-04-28 | Abraxis Bioscience, Llc | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
WO2007084667A2 (en) | 2006-01-19 | 2007-07-26 | Osi Pharmaceutical, Inc. | Fused heterobicyclic kinase inhibitors |
EP2037931A2 (en) | 2006-04-25 | 2009-03-25 | Astex Therapeutics Limited | Pharmaceutical combinations of pk inhibitors and other active agents |
WO2007125325A1 (en) | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Pharmaceutical compounds |
JP2009536161A (ja) | 2006-04-25 | 2009-10-08 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
JP2009534454A (ja) | 2006-04-25 | 2009-09-24 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
EP2043655A2 (en) | 2006-04-25 | 2009-04-08 | Astex Therapeutics Limited | Purine and deazapurine derivatives as pharmaceutical compounds |
US8247421B2 (en) | 2006-12-21 | 2012-08-21 | Vertex Pharmaceuticals Incorporated | 5-cyano-4-(pyrrolo [2,3B] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors |
AR064415A1 (es) | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb. |
AR064416A1 (es) | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas. |
PL2201012T3 (pl) * | 2007-10-11 | 2014-11-28 | Astrazeneca Ab | Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b |
AU2010210422A1 (en) * | 2009-02-05 | 2011-08-18 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens |
JP5059977B2 (ja) * | 2009-02-10 | 2012-10-31 | アストラゼネカ アクチボラグ | トリアゾロ[4,3−b]ピリダジン誘導体および前立腺癌のためのそれらの使用 |
EP2475366A1 (en) * | 2009-09-11 | 2012-07-18 | Bayer Pharma Aktiengesellschaft | Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs |
JP6042802B2 (ja) * | 2010-04-27 | 2016-12-14 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 新生物(腫瘍)を治療するための免疫原性組成物及び方法。 |
-
2012
- 2012-11-30 MY MYPI2014701394A patent/MY175800A/en unknown
- 2012-11-30 KR KR1020147016680A patent/KR102035361B1/ko active IP Right Grant
- 2012-11-30 PT PT127958429T patent/PT2785349T/pt unknown
- 2012-11-30 MX MX2014006547A patent/MX367640B/es active IP Right Grant
- 2012-11-30 SG SG11201401471PA patent/SG11201401471PA/en unknown
- 2012-11-30 CA CA2856646A patent/CA2856646C/en active Active
- 2012-11-30 FI FIEP12795842.9T patent/FI2785349T4/fi active
- 2012-11-30 CN CN201280059109.1A patent/CN103945849B/zh active Active
- 2012-11-30 SI SI201231690T patent/SI2785349T2/sl unknown
- 2012-11-30 HR HRP20191982TT patent/HRP20191982T4/hr unknown
- 2012-11-30 HU HUE12795842A patent/HUE046667T2/hu unknown
- 2012-11-30 US US14/361,718 patent/US20140329786A1/en not_active Abandoned
- 2012-11-30 RU RU2014119713A patent/RU2640485C2/ru active
- 2012-11-30 LT LT12795842T patent/LT2785349T/lt unknown
- 2012-11-30 ES ES12795842T patent/ES2762250T5/es active Active
- 2012-11-30 AU AU2012321110A patent/AU2012321110B2/en active Active
- 2012-11-30 DK DK12795842.9T patent/DK2785349T4/da active
- 2012-11-30 RS RS20191392A patent/RS59493B2/sr unknown
- 2012-11-30 EP EP12795842.9A patent/EP2785349B2/en active Active
- 2012-11-30 PL PL12795842.9T patent/PL2785349T5/pl unknown
- 2012-11-30 WO PCT/GB2012/052969 patent/WO2013079964A1/en active Application Filing
- 2012-11-30 AU AU2013205648A patent/AU2013205648B2/en active Active
- 2012-11-30 JP JP2014543977A patent/JP6309454B2/ja active Active
-
2014
- 2014-05-08 IL IL232530A patent/IL232530B/en active IP Right Grant
-
2015
- 2015-03-18 HK HK15102783.0A patent/HK1202253A1/xx unknown
-
2016
- 2016-02-08 US US15/018,157 patent/US9737540B2/en active Active
-
2019
- 2019-12-17 CY CY20191101323T patent/CY1122624T1/el unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080161404A1 (en) * | 2005-02-23 | 2008-07-03 | Astrazeneca Ab | Bicalutamide for Delivering Increasing Steady State Plasma Levels |
Non-Patent Citations (5)
Title |
---|
Attard et al. (Clinical Res. Published on line First March 3, 2011) * |
Baskin-Bey (3rd European Multidisciplinary Meeting on Urological Cancers . November 4-6, 2011 . Barcelona, Spain). * |
JAPIC Clinical Trials (Sept 9, 2011) * |
Scher et al. Lancet. 2010 April 24; 375(9724): 1437-1446 * |
Thomas et al ( Urology Volume 78, Issue 3, Supplement, September 2011, Pages S293) * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018015958A1 (en) | 2016-07-21 | 2018-01-25 | Hadasit Medical Research Services And Development Ltd. | Ar antagonists or inhibitors for use in treating glioblastoma |
US11478453B2 (en) | 2016-07-21 | 2022-10-25 | Hadasit Medical Research Services And Development Ltd. | Treatment for glioblastoma |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9737540B2 (en) | Combination treatment of cancer | |
AU2021290270A1 (en) | Method of treating cancer associated with a RAS mutation | |
JP2012515184A (ja) | 大腸がんの治療方法 | |
WO2021155764A1 (zh) | Bi853520与化疗药物的联用 | |
JP2018519266A (ja) | 心不全の治療のためのサクビトリル−バルサルタンの用量計画 | |
WO2013184621A1 (en) | Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease | |
US11938123B2 (en) | Use of 2,3,5-substituted thiophene compound to prevent, ameliorate, or treat breast cancers | |
US20130237549A1 (en) | Pharmaceutical combination | |
US20170326200A1 (en) | Method of Treating Prader-Willi Syndrome | |
TWI341728B (en) | Combinations comprising epothilones and anti-metabolites | |
TW202339726A (zh) | 用於治療癌症之與畢尼替尼(Binimetinib)併用之HDAC抑制劑OKI-179 | |
EP2694056B1 (en) | Therapeutic treatment | |
JP6708634B2 (ja) | 急性骨髄性白血病及び骨髄異形成症候群の併用療法iii | |
US20230038138A1 (en) | Combination therapy for treating cancer | |
NZ625611B2 (en) | Combination treatment of cancer | |
JP2014231518A (ja) | 子宮腫瘍の治療用医薬の調製のための7−t−ブトキシイミノメチルカンプトテシンの使用 | |
US20230089371A1 (en) | Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid | |
US20240197739A1 (en) | Combination Comprising Ribociclib and Amcenestrant | |
TW202308641A (zh) | 用於治療癌症之方法及包含cdk抑制劑之給藥方案 | |
BR112014012261B1 (pt) | Combinação e uso de (s)-4-amino-n-(1-(4-clorofenil)-3- hidroxipropil)-1-(7h-pirrolo [2,3-d] pirimidin-4-il)piperidina-4- carboxamida com um modulador da sinalização do receptor de androgênio |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ASTRAZENECA AB, SWEDEN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ASTRAZENECA UK LIMITED;REEL/FRAME:033207/0108 Effective date: 20121210 Owner name: ASTRAZENECA UK LIMITED, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DAVIES, BARRY ROBERT;REEL/FRAME:033207/0064 Effective date: 20121210 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |